Open access
Sep 2026
Host-derived immunometabolic biomarkers identify prognostic profiles under immunotherapy in advanced NSCLC: the SARC-LUNG study
Immune checkpoint inhibitors (ICIs) improve outcomes in advanced non-small cell lung cancer (NSCLC), but predictive biomarkers remain limited. Host-derived immunometabolic factors may modulate response to ICIs. In the prospective SARC-LUNG study, 40 patients with advanced NSCLC treated with first-line ICIs...
A. De Giglio, Maria Conte, Simona Coco et al.
· Cancer Immunology and Immuno... · 0 citations